In the present invention there is disclosed a pharmaceutical combination containing 2 to 8 mg of 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidine-24-dione (compound of the general formula I) or a tautomeric form and/or pharmaceutically acceptable derivative thereof and sulfonylurea wherein the sulfonylurea is represented by glibenclamide glipizide gliclazide glimepiride tolazamide or tolbutamide. There is also disclosed the use of the above-described combination in a pharmaceutical composition intended for the treatment of diabetes mellitus and/or conditions associated therewith.

暂无附图